Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Molecular Targets for Therapy

Targeting the PI3K/Akt/mTOR signaling pathway in B-precursor acute lymphoblastic leukemia and its therapeutic potential

Leukemia volume 28, pages 739–748 (2014)Cite this article

Subjects

Abstract

B-precursor acute lymphoblastic leukemia (B-pre ALL) is a malignant disorder characterized by the abnormal proliferation of B-cell progenitors. The prognosis of B-pre ALL has improved in pediatric patients, but the outcome is much less successful in adults. Constitutive activation of the phosphatidylinositol 3-kinase (PI3K), Akt and the mammalian target of rapamycin (mTOR) (PI3K/Akt/mTOR) network is a feature of B-pre ALL, where it strongly influences cell growth and survival. RAD001, a selective mTORC1 inhibitor, has been shown to be cytotoxic against many types of cancer including hematological malignancies. To investigate whether mTORC1 could represent a target in the therapy of B-pre ALL, we treated cell lines and adult patient primary cells with RAD001. We documented that RAD001 decreased cell viability, induced cell cycle arrest in G0/G1 phase and caused apoptosis in B-pre ALL cell lines. Autophagy was also induced, which was important for the RAD001 cytotoxic effect, as downregulation of Beclin-1 reduced drug cytotoxicity. RAD001 strongly synergized with the novel allosteric Akt inhibitor MK-2206 in both cell lines and patient samples. Similar results were obtained with the combination CCI-779 plus GSK 690693. These findings point out that mTORC1 inhibitors, either as a single agent or in combination with Akt inhibitors, could represent a potential therapeutic innovative strategy in B-pre ALL.

Access through your institution
Buy or subscribe

This is a preview of subscription content, access via your institution

Access options

Access through your institution

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7
Figure 8

Similar content being viewed by others

References

  1. Zhou Y, You MJ, Young KH, Lin P, Lu G, Medeiros LJ et al. Advances in the molecular pathobiology of B-lymphoblastic leukemia. Hum Pathol 2012; 43: 1347–1362.

    Article  CAS  PubMed  Google Scholar 

  2. Moorman AV . The clinical relevance of chromosomal and genomic abnormalities in B-cell precursor acute lymphoblastic leukaemia. Blood Rev 2012; 26: 123–135.

    Article  CAS  PubMed  Google Scholar 

  3. De Braekeleer E, Basinko A, Douet-Guilbert N, Morel F, Le Bris MJ, Berthou C et al. Cytogenetics in pre-B and B-cell acute lymphoblastic leukemia: a study of 208 patients diagnosed between 1981 and 2008. Cancer Genet Cytogenet 2010; 200: 8–15.

    Article  CAS  PubMed  Google Scholar 

  4. Chang F, Lee JT, Navolanic PM, Steelman LS, Shelton JG, Blalock WL et al. Involvement of PI3K/Akt pathway in cell cycle progression, apoptosis, and neoplastic transformation: a target for cancer chemotherapy. Leukemia 2003; 17: 590–603.

    Article  CAS  PubMed  Google Scholar 

  5. Martelli AM, Evangelisti C, Chappell W, Abrams SL, Basecke J, Stivala F et al. Targeting the translational apparatus to improve leukemia therapy: roles of the PI3K/PTEN/Akt/mTOR pathway. Leukemia 2011; 25: 1064–1079.

    Article  CAS  PubMed  Google Scholar 

  6. Willems L, Chapuis N, Puissant A, Maciel TT, Green AS, Jacque N et al. The dual mTORC1 and mTORC2 inhibitor AZD8055 has anti-tumor activity in acute myeloid leukemia. Leukemia 2012; 26: 1195–1202.

    Article  CAS  PubMed  Google Scholar 

  7. Silva A, Girio A, Cebola I, Santos CI, Antunes F, Barata JT . Intracellular reactive oxygen species are essential for PI3K/Akt/mTOR-dependent IL-7-mediated viability of T-cell acute lymphoblastic leukemia cells. Leukemia 2011; 25: 960–967.

    Article  CAS  PubMed  Google Scholar 

  8. Fuka G, Kantner HP, Grausenburger R, Inthal A, Bauer E, Krapf G et al. Silencing of ETV6/RUNX1 abrogates PI3K/AKT/mTOR signaling and impairs reconstitution of leukemia in xenografts. Leukemia 2012; 26: 927–933.

    Article  CAS  PubMed  Google Scholar 

  9. Thomas GV . mTOR and cancer: reason for dancing at the crossroads? Curr Opin Genet Dev 2006; 16: 78–84.

    Article  CAS  PubMed  Google Scholar 

  10. Vignot S, Faivre S, Aguirre D, Raymond E . mTOR-targeted therapy of cancer with rapamycin derivatives. Ann Oncol 2005; 16: 525–537.

    Article  CAS  PubMed  Google Scholar 

  11. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM . Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 2005; 307: 1098–1101.

    Article  CAS  PubMed  Google Scholar 

  12. Chapuis N, Tamburini J, Green AS, Willems L, Bardet V, Park S et al. Perspectives on inhibiting mTOR as a future treatment strategy for hematological malignancies. Leukemia 2010; 24: 1686–1699.

    Article  CAS  PubMed  Google Scholar 

  13. Martelli AM, Chiarini F, Evangelisti C, Cappellini A, Buontempo F, Bressanin D et al. Two hits are better than one: targeting both phosphatidylinositol 3-kinase and mammalian target of rapamycin as a therapeutic strategy for acute leukemia treatment. Oncotarget 2012; 3: 371–394.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Zhao YM, Zhou Q, Xu Y, Lai XY, Huang H . Antiproliferative effect of rapamycin on human T-cell leukemia cell line Jurkat by cell cycle arrest and telomerase inhibition. Acta Pharmacol Sin 2008; 29: 481–488.

    Article  CAS  PubMed  Google Scholar 

  15. Avellino R, Romano S, Parasole R, Bisogni R, Lamberti A, Poggi V et al. Rapamycin stimulates apoptosis of childhood acute lymphoblastic leukemia cells. Blood 2005; 106: 1400–1406.

    Article  CAS  PubMed  Google Scholar 

  16. Brown VI, Fang J, Alcorn K, Barr R, Kim JM, Wasserman R et al. Rapamycin is active against B-precursor leukemia in vitro and in vivo, an effect that is modulated by IL-7-mediated signaling. Proc Natl Acad Sci USA 2003; 100: 15113–15118.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Zhou H, Luo Y, Huang S . Updates of mTOR inhibitors. Anticancer Agents Med Chem 2010; 10: 571–581.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Nishioka C, Ikezoe T, Yang J, Koeffler HP, Yokoyama A . Blockade of mTOR signaling potentiates the ability of histone deacetylase inhibitor to induce growth arrest and differentiation of acute myelogenous leukemia cells. Leukemia 2008; 22: 2159–2168.

    Article  CAS  PubMed  Google Scholar 

  19. Witzig TE, Reeder CB, LaPlant BR, Gupta M, Johnston PB, Micallef IN et al. A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma. Leukemia 2011; 25: 341–347.

    Article  CAS  PubMed  Google Scholar 

  20. Yee KW, Zeng Z, Konopleva M, Verstovsek S, Ravandi F, Ferrajoli A et al. Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies. Clin Cancer Res 2006; 12: 5165–5173.

    Article  CAS  PubMed  Google Scholar 

  21. Hassane DC, Sen S, Minhajuddin M, Rossi RM, Corbett CA, Balys M et al. Chemical genomic screening reveals synergism between parthenolide and inhibitors of the PI-3 kinase and mTOR pathways. Blood 2010; 116: 5983–5990.

    Article  CAS  PubMed  Google Scholar 

  22. Levy DS, Kahana JA, Kumar R . AKT inhibitor, GSK690693, induces growth inhibition and apoptosis in acute lymphoblastic leukemia cell lines. Blood 2009; 113: 1723–1729.

    Article  CAS  PubMed  Google Scholar 

  23. Zaliova M, Madzo J, Cario G, Trka J . Revealing the role of TEL/AML1 for leukemic cell survival by RNAi-mediated silencing. Leukemia 2011; 25: 313–320.

    Article  CAS  PubMed  Google Scholar 

  24. Grimaldi C, Chiarini F, Tabellini G, Ricci F, Tazzari PL, Battistelli M et al. AMP-dependent kinase/mammalian target of rapamycin complex 1 signaling in T-cell acute lymphoblastic leukemia: therapeutic implications. Leukemia 2012; 26: 91–100.

    Article  CAS  PubMed  Google Scholar 

  25. Schult C, Dahlhaus M, Ruck S, Sawitzky M, Amoroso F, Lange S et al. The multikinase inhibitor Sorafenib displays significant antiproliferative effects and induces apoptosis via caspase 3, 7 and PARP in B- and T-lymphoblastic cells. BMC Cancer 2010; 10: 560.

    Article  PubMed  PubMed Central  Google Scholar 

  26. Shepherd C, Banerjee L, Cheung CW, Mansour MR, Jenkinson S, Gale RE et al. PI3K/mTOR inhibition upregulates NOTCH-MYC signalling leading to an impaired cytotoxic response. Leukemia 2013; 27: 650–660.

    Article  CAS  PubMed  Google Scholar 

  27. Fialin C, Larrue C, Vergez F, Sarry JE, Bertoli S, Mansat-De Mas V et al. The short form of RON is expressed in acute myeloid leukemia and sensitizes leukemic cells to cMET inhibitors. Leukemia 2013; 27: 325–335.

    Article  CAS  PubMed  Google Scholar 

  28. Morrison DJ, Hogan LE, Condos G, Bhatla T, Germino N, Moskowitz NP et al. Endogenous knockdown of survivin improves chemotherapeutic response in ALL models. Leukemia 2012; 26: 271–279.

    Article  CAS  PubMed  Google Scholar 

  29. Simioni C, Neri LM, Tabellini G, Ricci F, Bressanin D, Chiarini F et al. Cytotoxic activity of the novel Akt inhibitor, MK-2206, in T-cell acute lymphoblastic leukemia. Leukemia 2012; 26: 2336–2342.

    Article  CAS  PubMed  Google Scholar 

  30. Evangelisti C, Ricci F, Tazzari P, Chiarini F, Battistelli M, Falcieri E et al. Preclinical testing of the Akt inhibitor triciribine in T-cell acute lymphoblastic leukemia. J Cell Physiol 2011; 226: 822–831.

    Article  CAS  PubMed  Google Scholar 

  31. Zhang J, Xiao Y, Guo Y, Breslin P, Zhang S, Wei W et al. Differential requirements for c-Myc in chronic hematopoietic hyperplasia and acute hematopoietic malignancies in Pten-null mice. Leukemia 2011; 25: 1857–1868.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Saeki K, Yuo A, Okuma E, Yazaki Y, Susin SA, Kroemer G et al. Bcl-2 down-regulation causes autophagy in a caspase-independent manner in human leukemic HL60 cells. Cell Death Differ 2000; 7: 1263–1269.

    Article  CAS  PubMed  Google Scholar 

  33. Kim SI, Na HJ, Ding Y, Wang Z, Lee SJ, Choi ME . Autophagy promotes intracellular degradation of type I collagen induced by transforming growth factor (TGF)-beta1. J Biol Chem 2012; 287: 11677–11688.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Dall'Armi C, Devereaux KA, Di Paolo G . The role of lipids in the control of autophagy. Curr Biol 2013; 23: R33–R45.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Aziz SA, Jilaveanu LB, Zito C, Camp RL, Rimm DL, Conrad P et al. Vertical targeting of the phosphatidylinositol-3 kinase pathway as a strategy for treating melanoma. Clin Cancer Res 2010; 16: 6029–6039.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Ren H, Chen M, Yue P, Tao H, Owonikoko TK, Ramalingam SS et al. The combination of RAD001 and NVP-BKM120 synergistically inhibits the growth of lung cancer in vitro and in vivo. Cancer Lett 2012; 325: 139–146.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Zito CR, Jilaveanu LB, Anagnostou V, Rimm D, Bepler G, Maira SM et al. Multi-level targeting of the phosphatidylinositol-3-kinase pathway in non-small cell lung cancer cells. PLoS One 2012; 7: e31331.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Ewald F, Grabinski N, Grottke A, Windhorst S, Norz D, Carstensen L et al. Combined targeting of AKT and mTOR using MK-2206 and RAD001 is synergistic in the treatment of cholangiocarcinoma. Int J Cancer 2013 doi:10.1002/ijc.28214.

    Article  CAS  PubMed  Google Scholar 

  39. Hirai H, Sootome H, Nakatsuru Y, Miyama K, Taguchi S, Tsujioka K et al. MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo. Mol Cancer Ther 2010; 9: 1956–1967.

    Article  CAS  PubMed  Google Scholar 

  40. Tan S, Ng Y, James DE . Next-generation Akt inhibitors provide greater specificity: effects on glucose metabolism in adipocytes. Biochem J 2011; 435: 539–544.

    Article  CAS  PubMed  Google Scholar 

  41. Urashima M, Hoshi Y, Sugimoto Y, Kaihara C, Matsuzaki M, Chauhan D et al. A novel pre-B acute lymphoblastic leukemia cell line with chromosomal translocation between p16(INK4A)/p15(INK4B) tumor suppressor and immunoglobulin heavy chain genes: TGFbeta/IL-7 inhibitory signaling mechanism. Leukemia 1996; 10: 1576–1583.

    CAS  PubMed  Google Scholar 

  42. Brown VI, Seif AE, Reid GS, Teachey DT, Grupp SA . Novel molecular and cellular therapeutic targets in acute lymphoblastic leukemia and lymphoproliferative disease. Immunol Res 2008; 42: 84–105.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Choo AY, Blenis J . TORgeting oncogene addiction for cancer therapy. Cancer Cell 2006; 9: 77–79.

    Article  CAS  PubMed  Google Scholar 

  44. Kornblau SM, Womble M, Qiu YH, Jackson CE, Chen W, Konopleva M et al. Simultaneous activation of multiple signal transduction pathways confers poor prognosis in acute myelogenous leukemia. Blood 2006; 108: 2358–2365.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Zhou L, Huang Y, Li J, Wang Z . The mTOR pathway is associated with the poor prognosis of human hepatocellular carcinoma. Med Oncol 2010; 27: 255–261.

    Article  CAS  PubMed  Google Scholar 

  46. Liu D, Huang Y, Chen B, Zeng J, Guo N, Zhang S et al. Activation of mammalian target of rapamycin pathway confers adverse outcome in nonsmall cell lung carcinoma. Cancer 2011; 117: 3763–3773.

    Article  CAS  PubMed  Google Scholar 

  47. Hirashima K, Baba Y, Watanabe M, Karashima R, Sato N, Imamura Y et al. Phosphorylated mTOR expression is associated with poor prognosis for patients with esophageal squamous cell carcinoma. Ann Surg Oncol 2010; 17: 2486–2493.

    Article  PubMed  Google Scholar 

  48. Morishita N, Tsukahara H, Chayama K, Ishida T, Washio K, Miyamura T et al. Activation of Akt is associated with poor prognosis and chemotherapeutic resistance in pediatric B-precursor acute lymphoblastic leukemia. Pediatr Blood Cancer 2012; 59: 83–89.

    Article  PubMed  Google Scholar 

  49. Zeng Z, Sarbassov dos D, Samudio IJ, Yee KW, Munsell MF, Ellen Jackson C et al. Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AML. Blood 2007; 109: 3509–3512.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Evangelisti C, Ricci F, Tazzari P, Tabellini G, Battistelli M, Falcieri E et al. Targeted inhibition of mTORC1 and mTORC2 by active-site mTOR inhibitors has cytotoxic effects in T-cell acute lymphoblastic leukemia. Leukemia 2011; 25: 781–791.

    Article  CAS  PubMed  Google Scholar 

  51. Levine B, Kroemer G . Autophagy in aging, disease and death: the true identity of a cell death impostor. Cell Death Differ 2009; 16: 1–2.

    Article  CAS  PubMed  Google Scholar 

  52. Crazzolara R, Bradstock KF, Bendall LJ . RAD001 (Everolimus) induces autophagy in acute lymphoblastic leukemia. Autophagy 2009; 5: 727–728.

    Article  CAS  PubMed  Google Scholar 

  53. Grabinski N, Ewald F, Hofmann BT, Staufer K, Schumacher U, Nashan B et al. Combined targeting of AKT and mTOR synergistically inhibits proliferation of hepatocellular carcinoma cells. Mol Cancer 2012; 11: 85.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Floc'h N, Kinkade CW, Kobayashi T, Aytes A, Lefebvre C, Mitrofanova A et al. Dual targeting of the Akt/mTOR signaling pathway inhibits castration-resistant prostate cancer in a genetically engineered mouse model. Cancer Res 2012; 72: 4483–4493.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  55. Saunders P, Cisterne A, Weiss J, Bradstock KF, Bendall LJ . The mammalian target of rapamycin inhibitor RAD001 (everolimus) synergizes with chemotherapeutic agents, ionizing radiation and proteasome inhibitors in pre-B acute lymphocytic leukemia. Haematologica 2011; 96: 69–77.

    Article  CAS  PubMed  Google Scholar 

  56. Park S, Chapuis N, Saint Marcoux F, Recher C, Prebet T, Chevallier P et al. A phase Ib GOELAMS study of the mTOR inhibitor RAD001 in association with chemotherapy for AML patients in first relapse. Leukemia 2013; 27: 1479–1486.

    Article  CAS  PubMed  Google Scholar 

  57. Driscoll B, T'Ang A, Hu YH, Yan CL, Fu Y, Luo Y et al. Discovery of a regulatory motif that controls the exposure of specific upstream cyclin-dependent kinase sites that determine both conformation and growth suppressing activity of pRb. J Biol Chem 1999; 274: 9463–9471.

    Article  CAS  PubMed  Google Scholar 

  58. Brantley MA Jr. . Harbour JW. Inactivation of retinoblastoma protein in uveal melanoma by phosphorylation of sites in the COOH-terminal region. Cancer Res 2000; 60: 4320–4323.

    CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

This work was supported by grants from MinSan 2008 ‘Molecular therapy in pediatric sarcomas and leukemias against IGF-IR system: new drugs, best drug–drug interactions, mechanisms of resistance and indicators of efficacy’ (to AMM), MIUR PRIN 200938XJLA_003 (to SC) and MIUR FIRB 2010 (RBAP10447J_003 to AMM and RBAP10Z7FS_002 to SC).

Author information

Author notes

  1. L M Neri and A Cani: These authors contributed equally to this work.

Authors and Affiliations

  1. Department of Morphology, Surgery and Experimental Medicine, University of Ferrara, Ferrara, Italy

    L M Neri, A Cani, C Simioni & S Capitani

  2. Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy

    A M Martelli

  3. Institute of Molecular Genetics, National Research Council, Pavia, Italy

    A M Martelli

  4. Division of Medicine, Department of Hematology/Oncology/Palliative Medicine, University of Rostock, Rostock, Germany

    C Junghanss

  5. Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy

    G Tabellini

  6. Immunohematology and Transfusion Center, Policlinico S.Orsola-Malpighi, Bologna, Italy

    F Ricci, P L Tazzari & P Pagliaro

  7. Department of Microbiology and Immunology, Brody School of Medicine, East Carolina University, Greenville, NC, USA

    J A McCubrey

Authors
  1. L M Neri
    View author publications

    You can also search for this author inPubMed Google Scholar

  2. A Cani
    View author publications

    You can also search for this author inPubMed Google Scholar

  3. A M Martelli
    View author publications

    You can also search for this author inPubMed Google Scholar

  4. C Simioni
    View author publications

    You can also search for this author inPubMed Google Scholar

  5. C Junghanss
    View author publications

    You can also search for this author inPubMed Google Scholar

  6. G Tabellini
    View author publications

    You can also search for this author inPubMed Google Scholar

  7. F Ricci
    View author publications

    You can also search for this author inPubMed Google Scholar

  8. P L Tazzari
    View author publications

    You can also search for this author inPubMed Google Scholar

  9. P Pagliaro
    View author publications

    You can also search for this author inPubMed Google Scholar

  10. J A McCubrey
    View author publications

    You can also search for this author inPubMed Google Scholar

  11. S Capitani
    View author publications

    You can also search for this author inPubMed Google Scholar

Corresponding author

Correspondence to L M Neri.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Additional information

Supplementary Information accompanies this paper on the Leukemia website

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Cite this article

Neri, L., Cani, A., Martelli, A. et al. Targeting the PI3K/Akt/mTOR signaling pathway in B-precursor acute lymphoblastic leukemia and its therapeutic potential. Leukemia 28, 739–748 (2014). https://doi.org/10.1038/leu.2013.226

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/leu.2013.226

Keywords

This article is cited by

Search

Advanced search

Quick links